Objectives: We investigated the current agreement of 25(OH)D measurement in clinical laboratories and explored the possibility that simple calibration would improve between-laboratory agreement.
M easurement of circulating 25-hydroxy-vitamin D [25(OH)D] is accepted as the clinical indicator of vitamin D status (1). As such, 25(OH)D measurement has become
widely used by clinicians with diagnoses of low vitamin D status being made, and vitamin D supplementation prescribed, based upon these values. However, in the recent past, substantial between-laboratory variability has been present, making clinical assessment of the vitamin D status of individual patients problematic (2) (3) (4) . It might be assumed that the recent widespread clinical availability of liquid chromatography tandem mass spectroscopy (LCMSMS) and HPLC (3) technologies has improved 25(OH)D assay performance, thereby improving agreement between measurements obtained at different clinical laboratories. However, a review of recent vitamin D External Quality Assessment Scheme (DEQAS) data revealed substantial variability in individual 25(OH)D results between laboratories using LCMSMS and HPLC, despite good agreement of mean values. We hypothesized that this interlaboratory variability may reflect differences in assay calibration. The use of one or more externally supplied "calibrators," containing an established value of 25(OH)D, could potentially be used to standardize assay performance. To evaluate the current clinical status of 25(OH)D measurement in the United States and investigate the possibility that simple assay calibration would improve between-laboratory agreement, 15 serum specimens and one "calibrator," selected to have a 25(OH)D value near 30 ng/ml, were analyzed in four clinical laboratories.
Subjects and Methods

DEQAS 25(OH)D data
As part of quality control measures, over 200 laboratories worldwide participate in the DEQAS. The overall aim of this voluntary effort is to ensure analytical reliability of vitamin D assays. This is achieved through quarterly distribution of serum pools (n ϭ 5 specimens) with subsequent reporting of these results to participants. Various methodologies are used for 25(OH)D measurement by laboratories participating in the DEQAS, including RIA, HPLC, and LCMSMS. DEQAS data are reported to participating laboratories in aggregate form with mean values reported. However, individual laboratory values are reported anonymously for HPLC and LCMSMS methods. The example data presented here are from the April, 2006, quarterly specimen distribution.
Study participants/clinical 25(OH)D measurement
Blood was obtained from 15 generally healthy adults (eight females, seven males; age 20 -60 yr) by routine venipuncture, allowed to clot for 30 min at room temperature, then centrifuged. Study participants had no known acute or life-threatening illnesses and chemistry panels without clinically significant abnormalities. Serum aliquots were prepared and frozen at Ϫ80 C until shipped in a routine clinical manner for analysis. Aliquots of serum from one individual were obtained to serve as a "cal- (Table 1 ). This work was approved by the University of Wisconsin Health Sciences institutional review board; informed consent was obtained from all study participants.
Data analysis
Based upon lowest self-reported percent CV, serum 25(OH)D results from laboratory A were defined for the purposes of this report as the "gold standard" to which the other laboratories were compared. Clinical vitamin D status was defined by serum 25(OH)D measurement as follows: optimal vitamin D status, more than or equal to 30 ng/nl; low vitamin D status, less than 30 ng/ml. Serum 25(OH)D measurements from the four laboratories were compared using linear regression and Bland-Altman analyses (Analyse-it; Analyse-it Software, Ltd., Leeds, 
Results
DEQAS 25(OH)D data
Results are arbitrarily presented for two serum specimens (defined here as "1" and "2"). For these two sera, good agreement was reported for the mean 25(OH)D value from laboratories using HPLC (n ϭ 9), LCMSMS (n ϭ 8), and the DiaSorin RIA (n ϭ 54) methodologies. Specifically, the mean (SD) values reported for these three technologies were 35.7 (8.4), 34.6 (7.3), and 31.4 (6.4) ng/ml for serum 1, and 25.5 (7.1), 28.9 (5.0), and 26.4 (5.6) ng/ml for serum 2, respectively.
The DEQAS reports individual values for those laboratories using HPLC or LCMSMS, which upon review appear to demonstrate substantial between-laboratory variability (Fig. 1A) . Evaluation of 25(OH)D results for these two sera by individual laboratory using HPLC methodology identifies what may be a systematic offset that suggests the possibility that assay calibration differences might explain some of the between-laboratory differences (Fig. 1B) .
Clinical 25(OH)D analysis
Of these 15 specimens, 10 contained only 25(OH)D 3 as identified by HPLC. In the remaining five specimens, the 25(OH)D 2 concentration ranged from 5-19 ng/ml. Because clinical decisions are made based upon the total 25(OH)D concentration, this value was used for between-laboratory comparison. Diagnostic categorization (optimal vs. low vitamin D status) was identical in 80% (12 of 15) of subjects (Fig. 2) . Good correlation was observed between laboratory A and the other three laboratories (R 2 ϭ 0.99, 0.81, and 0.95) (Fig. 3, A-C) . However, modest between-laboratory variability was noted; the mean bias of laboratories B-D ranged from ϩ2.9 to ϩ5.1 ng/ml when compared with laboratory A (example in Fig. 3D ). This systematic positive bias leads to 89% (40 of 45) of values being higher in laboratories B-D than the corresponding laboratory A value (Fig. 4) . "Correction" of the 25(OH)D values obtained by laboratories B-D reduces the mean bias (Fig.  5, A-C) , e.g. after correction, laboratories A and B obtain virtually identical results (Fig. 5, A and D) .
Discussion
Overall, there is good agreement of serum 25(OH)D determination between clinical laboratories using HPLC, LCMSMS, and a RIA methodology. However, modest variability and systematic bias are present between clinical laboratories. Based upon this variability, patients of clinicians who use a "cutpoint" diagnostic approach (e.g. 30 ng/ml) will continue to be variably identified as having low vitamin D status depending on the laboratory in which 25(OH)D measurement is performed. The presence of systematic bias between laboratories suggests that the use of a standardized calibrator, or calibrators, will enhance between-laboratory agreement. In addition, it is noteworthy that these data suggest better between-laboratory agreement at lower serum 25(OH)D concentrations, an observation concurrent with prior reports (3, 6) .
There has been considerable discussion of what constitutes optimal vitamin D status and what cutpoint to use for a clinical diagnosis of vitamin D "deficiency" or "inadequacy." (7-9) As could be expected, the prevalence of low D status is highly dependent upon the cutpoint selected (10) . Nonetheless, there is increasing clinical consensus that values less than 30 -32 ng/ml are indicative of suboptimal vitamin D status (7). It is important for clinicians to recognize that any such arbitrary cutpoint will have variability surrounding the value chosen from both analytical and biological sources. Specifically, analytical imprecision is present in all quantitative medical procedures due to human and instrument limitations. In addition, at this point in time, there is no internationally recognized primary standard, however, the National Institute of Standards and Technology is currently working to rectify this situation. Based upon these results, availability of standards should enhance betweenlaboratory agreement.
In addition to analytical variability, within-individual biolog- for a 25(OH)D concentration of approximately 40 ng/ml. This suggestion is based upon the increasingly accepted recommendation that a 25(OH)D concentration of more than or equal to 30 ng/ml be considered optimal, combined with the reported approximate 20% within-individual variability (i.e. 6 ng/ml if one targets 30 ng/ml) and the approximate 5 ng/ml systematic bias reported here. We recognize that some individuals with a serum 25(OH)D value of 40 ng/ml could truly have a value greater than this, but given the wide margin of safety reported for vitamin D, such a recommendation seems clinically prudent to ensure that the vitamin D status of an individual is optimal (Ͼ30 ng/ml).
Limitations of this study include the small sample size, limited population studied, and the fact that not all methodologies available for 25(OH)D measurement were evaluated. In this regard, it was our intent to compare the performance of 25(OH)D assays clinically available to us; we did not seek to evaluate all available assays or results performed in research settings. However, with the interest in automated technology, we did evaluate one such instrument, the DiaSorin Liaison in a research environment. In this setting, we found good correlation (R 2 ϭ 0.95) with laboratory A but feel it not justifiable to include as primary data because we did not have access to this technology in a routine clinical setting. Finally, we recognize that it is possible that other technologies and the study of other populations would provide differing results than reported here.
In conclusion, there is good agreement of serum 25(OH)D measured in these four clinical laboratories. Between-laboratory agreement should be improved with the use of standard calibrators. Based upon analytical and biological variability, it seems prudent that clinicians target a serum 25(OH)D value greater than 30 ng/ml to ensure vitamin D adequacy in their patients.
